Overview

* Humacyte ( HUMA ) Q2 revenue of $0.3 mln missed analyst expectations, per LSEG data

* Net loss for Q2 narrows to $37.7 mln, but misses analyst estimates, per LSEG data

* Co achieved significant progress in Symvess market launch with VAC and ECAT approvals

Outlook

* Company plans to submit supplemental BLA in 2026 for Symvess AV access

* Humacyte ( HUMA ) sees acceleration in VAC approvals for Symvess

* Company in discussions with additional DOD facilities for Symvess sales

* Humacyte ( HUMA ) plans further clinical trials for ATEV in dialysis

Result Drivers

* VAC APPROVALS - Significant increase in VAC approvals expanded Symvess eligibility from 5 to 82 civilian hospitals, per CEO Laura Niklason

* ECAT LISTING - ECAT approval enables Symvess availability at 35 Military Treatment Facilities and 160 VA hospitals

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $301,000 $1 mln

Revenue (6

Analysts

)

Q2 Net Miss -$37.66 -$22.80

Income mln mln (6

Analysts

)

Q2 Miss -$29.73 -$22.30

Operatin mln mln (6

g Income Analysts

)

Q2 Basic -$0.24

EPS

Q2 $30.03

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Humacyte Inc ( HUMA ) is $6.50, about 61.8% above its August 8 closing price of $2.48

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)